Skip to main content
Journal of Clinical & Translational Endocrinology logoLink to Journal of Clinical & Translational Endocrinology
. 2017 Jun 29;9:32–37. doi: 10.1016/j.jcte.2017.06.001

Diabetic osteoarthropathy care in Sweden – Need for improvement: A national inventory

Linda Wennberg a,, Paul Lundgren b, Rimma Axelsson c, Peter Aspelin c, Kurt Gerok-Andersson d, Börje Åkerlund e
PMCID: PMC5651304  PMID: 29067267

Highlights

  • 79% of the clinics had no guidelines for managing patients with osteoarthropathy.

  • Only two clinics presented acceptable guidelines.

  • Plain X-ray, was the common diagnostic method.

Keywords: Diabetes, Osteoarthropathy, Charcot foot, National inventory

Abstract

Aims

Osteoarthropathy, a rare foot complication in patients with diabetes mellitus, calls for immediate and optimal management to prevent irreversible bone/joint destruction and risk of amputation. Awareness of the condition and adequate guidelines would minimize the consequences and the costs, both for the patient and for the society. We investigated the diabetic osteoarthropathy care in Swedish orthopedic clinics.

Methods

A questionnaire was distributed to 63 Swedish hospitals with emergency department for orthopedic patients. There was a 95% response rate.

Results

Most of the respondents (79%) specified absence of established procedures including guidelines for managing patients with osteoarthropathy. The most common diagnostic method was clinical diagnosis and plain X-ray (95%). MRI or scintigraphy was used by 19% and 10.5% respectively. As treatment method, 84% used a total contact cast, while 38% used orthoses. Treatment duration <3 months was reported in 4%, 3–6 months in 53% and 6–12 months in 28% of the clinics. Four clinics reported treatment duration >12 months and two clinics provided no treatment.

Conclusion

Our national inventory indicates a need for improvement in knowledge as well as guidance and organization at orthopedic clinics regarding optimal care of patients with diabetic osteoarthropathy.

Introduction

Neuropathic foot arthropathy was first described in patients with tabes dorsalis by Jean-Marie Charcot in 1868 [1]. The association between osteoarthropathy and diabetes mellitus was presented by Jordan [2]. Despite the condition being known for such a long time the diagnostic and treatment options have been limited. However, the reconstruction techniques for unavoidable osteoarthropathy foot deformity have substantially improved during the 20th century [3].

The diagnosis of diabetic osteoarthropathy today is associated with already affected and fractured bones. This will require advanced reconstructive surgery including a long rehabilitation period with reduced mobility for the patient. Moreover, there will be a risk for amputation if the osteoarthropathy is complicated by chronic ulcers and/or chronic infections [4].

As the current diagnosis is based on plain X-ray findings with a destruction of the foot skeleton (Fig. 1a-b) the condition, to some extent, has already become too aggravated to heal without sequelae. New diagnostic methods facilitating earlier diagnosis is therefore imperative. More advanced diagnostic tools have been evaluated, with MRI (magnetic resonance imaging) emerging as highly sensitive for the early detection of osteoarthropathy. Unfortunately, due to the similarities with osteomyelitis, the specificity of MRI is unsatisfactory but MRI could probably be a valuable diagnostic alternative [5], [6], [7]. Bone scintigraphy is another imaging technique which shows a high sensitivity for bone pathology with increased uptake in patients with osteoarthropathy [8]. Impaired circulation can, however, result in a false-negative result and the uptake of the radionuclide tracers used is not specific for osteoarthropathy [9]. Positron emission tomography (PET) scanning with 18F-FDG has been proposed as a possible diagnostic pathway [10], [11]. However, more research is necessary before this technique can be applied in clinical practice.

Fig. 1.

Fig. 1

Plain anteroposterior X-ray (A-B), on diabetic patient presenting with a hot swollen right foot which was considered as degenerative changes without signs of osteoarthropathy (A). New X-ray 4 month later showed signs consistent with osteoarthropathy (B).

There have been different pathophysiological models for osteoarthropathy. The original French theory is based on Charcot’s studies of ataxia and finds the cause of the condition in lesions in the spinal cord.

The German theory, as promoted by Volkman and Virchow, focuses on multiple traumas to the joints. The neurovascular theory which could be connected with the French suggests that a neurally initiated vascular reflex leads to activation of osteoclasts and thereby bone resorption and fragility of the bone [2]. However, none of these theories provide a comprehensive explanation for diabetes osteoarthropathy.

Recently the inflammatory role of the condition especially receptor activator of the nuclear factor kappa B ligand (RANKL), NF-кB and osteopotegerin (OPG) has been thoroughly discussed [12], [13], [14]. With better understanding of the inflammatory mechanisms new therapeutical options seems possible.

The current treatment is focused on an immediate reduction of the bone-altering effects of the inflammatory condition. This usually implies long treatment periods of total off-loading with casts/orthosis and with non-weight bearing regimes and a considerable risk of low compliance.

Although diabetic osteoarthropathy is a rare foot complication with an estimated incidence of 0, 8–8% [15] the impact for the patient will be a reduced quality of life [16], [17], [18] including anxiety and depression [19] and for the society substantial health economical costs [20].

The condition is by our experience overlooked and often missed- and/or late diagnosed and there is in Sweden currently no information available regarding the caregiving of this patient group.

The purpose of this study was to make a national inventory of orthopedic caregivers’ organization for the diagnosis and treatment of diabetic osteoarthropathy.

Methods

This descriptive and cross-sectional study was carried out during the spring and early summer of 2014. Based on a registry from the Swedish Association of Local Authorities and Regions (SKL), 73 hospitals with emergency departments for orthopedic patients were identified. Since 14 of the hospitals were so-called “joint orthopedic clinics” with shared organizational structure, 63 units were chosen to investigate orthopedic caregiver’s organization for diagnosing and managing patients with suspected diabetic osteoarthropathy. The heads of the orthopedic clinics at each hospital were contacted to identify the orthopedic surgeon responsible for the care of patients with foot complications. The orthopedic surgeons were then contacted by e-mail with a description of the project’s purpose.

Data were collected using a structured questionnaire addressed directly to the orthopedic surgeon at each orthopedic clinic, requesting a response within 2 weeks. The questionnaire consisted of 8 questions mainly regarding diagnosis and treatment of patients with diabetic osteoarthropathy.

The respondents were also asked to include the clinic's current guidelines for diabetic osteoarthropathy management when returning the questionnaire.

The responses received were compiled without identifying individual units because the questionnaires were coded. The data were downloaded into Microsoft Excel, and analyzed and computed in terms of frequencies and percentages using the Statistical Package for Social Sciences (SPSS) Windows version 22.0. The received guidelines were assessed using diabetic (Charcot) foot management directives from the American Academy of Orthopaedic Surgeons (AAOS).

Results

We received answers from 60 clinics representing a 95% response rate (60/63). Three respondents stated that they have never dealt with patients with diabetic osteoarthropathy and therefore the analysis is based on responses from 57 clinics.

The estimated annual number of patients with diabetic osteoarthropathy is presented in Fig. 2.

Fig. 2.

Fig. 2

Estimated number of patients with diabetic osteoarthropathy seen annually.

Two of the responding clinics stated that they did not know whether they had any established guidelines for managing patients with diabetic osteoarthropathy. Most of the respondents, 45 clinics (79%), said they had no guidelines. Ten clinics reported that they had guidelines and seven of those attached them to the questionnaire. Upon evaluating these guidelines, only two could attain the level of management procedures recommended by the AAOS [21].

Diagnosis

Fifty clinics used more than one method for diagnosing osteoarthropathy and the most common diagnostic methods were clinical diagnosis and plain X-ray (Fig. 3).

Fig. 3.

Fig. 3

Methods for diagnosis of diabetic osteoarthropathy. A) Clinical diagnosis. B) Plain X-ray. C) MRI. D) Skin temperature. E) Bone scintigraphy. F) Replied that they did not know.

The period of time from suspected diabetic osteoarthropathy until the patient obtained an appointment at the clinic is presented in Table 1. Most of the clinics scheduled the patient between 1–5 days or after more than 5 days.

Table 1.

Period of time after suspected diabetic osteoarthropathy until obtained appointment at the clinic.

Obtained appointment after suspicion of diabetic osteoarthropathy Percentage (%)
(n = 57)
Don’t know 11 (19.3%)
Within one day 2 (3.5%)
1–5 days 26 (45.6%)
>5 days 18 (31.6%)

Treatment

As their treatment method, 17 of the clinics stated that they used different casting methods (Table 2), whereof 47 (84%) used a total contact cast and 21 (38%) orthosis. The most frequently used orthosis was the Aircast walker, at 27 institutions (47%). Six clinics (11%) also used individually adapted orthosis and in a few cases additional options were also specified such as the Don Joy Walker (2%), the Walker from Össur (2%) and PTB Orthosis (2%). Ten of the respondent clinics specified an orthosis option even though they had only listed the total contact cast as a treatment method.

Table 2.

Treatment methods for diabetic osteoarthropathy.

Treatment Percentage (%)
(n = 57)
Only total contact cast (TCC) 31 (54.4%)
Only orthoses 5 (8.8%)
Only bivalve cast (removable cast) 1 (1.8%)
Total contact cast and orthoses 12 (21%)
Total contact cast and bivalve cast 1 (1.8%)
Bivalve cast and orthoses 1 (1.8%)
Total contact cast, orthoses and bivalve cast 3 (5.2%)
Do not know 3 (5.2%)

Two clinics indicated a treatment duration of less than 3 months, thirty clinics (53%) a treatment duration of 3–6 months and sixteen clinics (28%) a duration of 6–12 months. Only four clinics indicated duration longer than 12 months, while two clinics provided no treatment at all.

The data derived from this study show that 34 of the 57 clinics claim to have access to reconstructive foot surgery for diabetic osteoarthropathy. Eleven referred the patient to the nearest university hospital and nine to the regional hospital. Two clinics stated that they did not know and one referred the patients to other unspecified clinics.

Discussion

To the best of our knowledge, there are currently no official reports at a national level on the prevalence of diabetic osteoarthropathy. However, it is likely that many cases are undiagnosed due to the health care system’s lack of recognition of the typical acute manifestation of diabetes osteoarthropathy [15]. Based on the data derived from our study we can only estimate the number of patients managed annually at each orthopedic clinic.

When reviewing the few guidelines provided by participating clinics, the lack of scientific basis for the guidelines became evident. This absence of evidence-based recommendations may partly explain the absence of printed guidelines from the participating clinics. Nevertheless, the AAOS recommendations presented on their website seem widespread and emphasize early diagnosis, treatment with non-weight bearing casts and long periods of treatment [21]. Based on this information, we found that out of seven provided guidelines, only two can be considered acceptable. This observation of non-existing guidelines in Sweden is in accordance with a recently published Danish study [22]. Another recent study from Michigan, USA [23] also indicate the importance of education as well as need for guidelines about Charcot neuroarthropathy for referring providers and more efficient referral processes. It is also noteworthy that even the recommendation from the AAOS is somewhat controversial and, for instance, indicates a much shorter time of treatment than is recommended by others [24].

To avoid deformity, the early osteoarthropathy diagnosis is of utmost importance for initiation of treatment. If a radiological method should be used, the method must be able to detect the condition in the acute phase before any bone destruction. The data derived from this study show that plain radiography is the most used method even though it will not show the early pathological bone changes [25]. Instead, MRI could possibly be used to visualize subchondral bone marrow edema with or without microfractures [26], [27], [28].

Only six clinics stated that they used bone scintigraphy as a diagnostic method even though it has a high sensitivity for detection of diabetic osteoarthropathy. The specificity is, however, considered to be insufficient for the diagnosis of the condition [29]. A hybrid PET/CT technique (positron emission tomography combined with computed tomography) that provides both metabolic and structural information in one imaging session would contribute to the diagnosis of osteoarthropathy [30]. However, this method was not included as an alternative in the questionnaire because it is currently under evaluation and is not considered as a clinical routine in Swedish hospitals.

Another issue that could merit further discussion is the fact that we did not specifically ask for the policy regarding weight bearing/non-weight bearing off-loading. Treatment with casts could possibly indicate non-weight bearing and orthosis a more weight bearing solution. A high number of clinics answered that they use both cast and weight bearing (21%). An explanation for this answer could be that those clinics start with a non-weight–bearing, total contact cast and later change to an orthosis when possible weight bearing is allowed.

Regarding the question of the availability of reconstructive surgery at the home clinic, the reported number is surprisingly high (60%). One explanation for this result could be that surgeons responding to the questionnaire were not aware of the competence needed for this complicated reconstructive surgery. Even though there might be some general foot surgeons at the clinic, this does not necessarily mean that they could perform this kind of advanced surgery. They in turn may actually refer these patients to specific foot surgery departments, without the respondent being aware of it.

A weakness of our study is that the primary care physicians who might be the patient’s first health care contact were not part of the inventory. Our findings indicate the need for further assessment of the caregiving of these patients also at the primary care level. However, we believe that as diabetes osteoarthropathy is an orthopedic issue, especially when it comes to reconstructive surgery, it demands the highest and optimal mindset at the orthopedic clinic to reduce the consequences of this rather rare but devastating diabetic foot complication. The knowledge of the orthopedic clinics should then actively and regularly be transferred to the primary care level.

In summary, this inventory clearly indicates a national need for an improvement in knowledge as well as guidance and organization regarding the care of patients with diabetic osteoarthropathy, since only two of 63 clinics presented useful guidelines. We also advocate national inventories of the care of diabetic osteoarthropathy in all developed countries to create a more optimal and equal and care for this rare but important foot complication in patients with diabetes. We strongly recommend a multidisciplinary and value based approach [31] to this diabetic foot complication in order to minimize the consequences for the patient and the costs for the society. In addition, we see a need for international consensus discussions in order to improve diagnosis and management of patients with suspected diabetic osteoarthropathy. An improved management will reduce the risk of foot deformity with less need of surgical reconstruction and risk for amputation.

Contribution of authors

L.W. assisted with the study design, collected research data, conducted data analyses and wrote the manuscript. P.L. assisted with design of the questionnaire and data analyses and wrote part of the manuscript. R.A. and P.A. contributed to discussions and reviewed and edited the questionnaire and manuscript. K.G.A. reviewed and edited the manuscript. B.Å. designed the questionnaire, supervised the study and reviewed and edited the manuscript. L.W and P.L are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of interest

No competing interest declared

Acknowledgments

We would like to thank the Swedish Association of Local Authorities and Regions for the list of emergency hospitals and the orthopedic clinics that contributed data to this study.

The study was performed in the context of a doctoral thesis at the Karolinska Institute’s Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Radiography, and was partly funded by the Swedish Diabetic Association.

Appendix A

graphic file with name fx1.jpg

References

  • 1.Sanders L.J., Edmonds M.E., Jeffcoate W.J. Who was first to diagnose and report neuropathic arthropathy of the foot and ankle: Jean-Martin Charcot or Herbert William Page? Diabetologia. 2013;56:1873–1877. doi: 10.1007/s00125-013-2961-6. [DOI] [PubMed] [Google Scholar]
  • 2.Jordan W.R. Neuritic manifestations in diabetes mellitus. Arch Intern Med. 1936;53:307–366. [Google Scholar]
  • 3.Petrova N.L., Edmonds M.E. Conservative and pharmacologic treatments for the diabetic charcot foot. Clin Podiatr Med Surg. 2017;34:15–24. doi: 10.1016/j.cpm.2016.07.003. [DOI] [PubMed] [Google Scholar]
  • 4.Sohn M.W., Stuck R.M., Pinzur M., Lee T.A., Budiman-Mak E. Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer. Diabetes Care. 2010;33:98–100. doi: 10.2337/dc09-1497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Höpfner S., Krolak C., Kessler S., Tiling R., Brinkbäumer K., Hahn K. Preoperative imaging of Charcot neuroarthropathy in diabetic patients: comparison of ring PET, hybrid PET, and magnetic resonance imaging. Foot Ankle Int/Am Orthop Foot Ankle Soc [and] Swiss Foot Ankle Soc. 2004;25:890–895. doi: 10.1177/107110070402501208. doi:868990 [pii] [DOI] [PubMed] [Google Scholar]
  • 6.Abdel Razek A.A.K., Samir S. Diagnostic performance of diffusion-weighted MR imaging in differentiation of diabetic osteoarthropathy and osteomyelitis in diabetic foot. Eur J Radiol. 2017;89:221–225. doi: 10.1016/j.ejrad.2017.02.015. [DOI] [PubMed] [Google Scholar]
  • 7.McCarthy E., Morrison W.B., Zoga A.C. MR imaging of the diabetic foot. Magn Reson Imaging Clin N Am. 2017;25:183–194. doi: 10.1016/j.mric.2016.08.005. [DOI] [PubMed] [Google Scholar]
  • 8.Pickwell K.M., van Kroonenburgh M.J., Weijers R.E., van Hirtum P.V., Huijberts M.S., Schaper N.C. F-18 FDG PET/CT scanning in charcot disease: a brief report. Clin Nucl Med. 2011;36:8–10. doi: 10.1097/RLU.0b013e3181feeb30. [DOI] [PubMed] [Google Scholar]
  • 9.Rogers L.C., Frykberg R.G., Armstrong D.G., Boulton A.J.M., Edmonds M., Van G.H. The Charcot foot in diabetes. Diabetes Care. 2011;34:2123–2129. doi: 10.2337/dc11-0844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Basu S., Chryssikos T., Houseni M., Scot Malay D., Shah J., Zhuang H. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot’s neuroarthropathy from osteomyelitis and soft-tissue infection? Nucl Med Commun. 2007;28:465–472. doi: 10.1097/MNM.0b013e328174447f. [DOI] [PubMed] [Google Scholar]
  • 11.Shagos G.S., Shanmugasundaram P., Varma A.K., Padma S., Sarma M. 18-F flourodeoxy glucose positron emission tomography-computed tomography imaging: a viable alternative to three phase bone scan in evaluating diabetic foot complications? Indian J Nucl Med. 2015;30:97–103. doi: 10.4103/0972-3919.152946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Petrova N.L., Dew T.K., Musto R.L., Sherwood R.A., Bates M., Moniz C.F. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy. Diabet Med. 2015;32:267–273. doi: 10.1111/dme.12590. [DOI] [PubMed] [Google Scholar]
  • 13.La Fontaine J., Lavery L., Jude E. Current concepts of Charcot foot in diabetic patients. Foot. 2016;26:7–14. doi: 10.1016/j.foot.2015.11.001. [DOI] [PubMed] [Google Scholar]
  • 14.Mabilleau G., Petrova N.L., Edmonds M.E., Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51:1035–1040. doi: 10.1007/s00125-008-0992-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rajbhandari S., Jenkins R., Davies C., Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia. 2002;45:1085–1096. doi: 10.1007/s00125-002-0885-7. [DOI] [PubMed] [Google Scholar]
  • 16.Sochocki M.P., Verity S., Atherton P.J., Huntington J.L., Sloan J.A., Embil J.M. Health related quality of life in patients with Charcot arthropathy of the foot and ankle. Foot Ankle Surg. 2008;14:11–15. doi: 10.1016/j.fas.2007.07.003. [DOI] [PubMed] [Google Scholar]
  • 17.Pakarinen T.-K., Laine H.-J., Mäenpää H., Mattila P., Lahtela J. Long-term outcome and quality of life in patients with Charcot foot. Foot Ankle Surg. 2009;15:187–191. doi: 10.1016/j.fas.2009.02.005. [DOI] [PubMed] [Google Scholar]
  • 18.Pinzur M.S., Evans A. Health-related quality of life in patients with Charcot foot. Am J Orthop (Belle Mead NJ) 2003;32:492–496. [PubMed] [Google Scholar]
  • 19.Chapman Z., Shuttleworth C.M., Huber J. High levels of anxiety and depression in diabetic patients with Charcot foot. J Foot Ankle Res. 2014;7:22. doi: 10.1186/1757-1146-7-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Labovitz J.M., Shofler D.W., Ragothaman K.K. The impact of comorbidities on inpatient Charcot neuroarthropathy cost and utilization. J Diabetes Complications. 2016;30:710–715. doi: 10.1016/j.jdiacomp.2016.01.004. [DOI] [PubMed] [Google Scholar]
  • 21.American academy of orthopaedic surgeons. Diabetic (Charcot) Foot-OrthoInfo - AAOS n.d. http://orthoinfo.aaos.org/topic.cfm?topic=A00655 (accessed March 22, 2017).
  • 22.Jansen R.B., Svendsen O.L., Kirketerp-Møller K. Clinical management of acute diabetic Charcot foot in Denmark. Dan Med J. 2016;63 [PubMed] [Google Scholar]
  • 23.Schmidt B.M., Wrobel J.S., Holmes C.M. Physician knowledge of a rare foot condition – influence of diabetic patient population on self-described knowledge and treatment. Clin Diabetes Endocrinol. 2017;3:2. doi: 10.1186/s40842-017-0041-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Game F.L., Catlow R., Jones G.R., Edmonds M.E., Jude E.B., Rayman G. Audit of acute charcot’s disease in the UK: the CDUK study. Diabetologia. 2012;55:32–35. doi: 10.1007/s00125-011-2354-7. [DOI] [PubMed] [Google Scholar]
  • 25.Chantelau E. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture. Diabet Med. 2005;22:1707–1712. doi: 10.1111/j.1464-5491.2005.01677.x. [DOI] [PubMed] [Google Scholar]
  • 26.Chantelau E., Poll L.W. Evaluation of the diabetic charcot foot by MR imaging or plain radiography - An observational study. Exp Clin Endocrinol Diabetes. 2006;114:428–431. doi: 10.1055/s-2006-924229. [DOI] [PubMed] [Google Scholar]
  • 27.Schlossbauer T., Mioc T., Sommerey S., Kessler S.B., Reiser M.F., Pfeifer K.-J. Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms. Eur J Med Res. 2008;13:409–414. [PubMed] [Google Scholar]
  • 28.Ruotolo V., Di Pietro B., Giurato L., Masala S., Meloni M., Schillaci O. A New Natural History of Charcot Foot. Clin Nucl Med. 2013;38:506–509. doi: 10.1097/RLU.0b013e318292eecb. [DOI] [PubMed] [Google Scholar]
  • 29.Dissanayake S.U., Bowling F.L., Jude E.B. The diabetic Charcot foot. Curr Diabetes Rev. 2012;8:191–194. doi: 10.2174/157339912800563981. [DOI] [PubMed] [Google Scholar]
  • 30.Keidar Z., Militianu D., Melamed E., Bar-Shalom R., Israel O. The diabetic foot: initial experience with 18F-FDG PET/CT. J Nucl Med. 2005;46:444–449. [PubMed] [Google Scholar]
  • 31.Porter M.E., Larsson S., Lee T.H. Standardizing patient outcomes measurement. N Engl J Med. 2016;374:504–506. doi: 10.1056/NEJMp1511701. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical & Translational Endocrinology are provided here courtesy of Elsevier

RESOURCES